(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/170793 A1

(51) International Patent Classification:
A61K 31/40 (2006.01) *A61K 31/4439* (2006.01)
A61P 35/00 (2006.01) *A61P 35/04* (2006.01)

(21) International Application Number:
PCT/EP2021/054815

(22) International Filing Date:
26 February 2021 (26.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20305190.9 27 February 2020 (27.02.2020) EP

(71) Applicant: **SANOFI** [FR/FR]; 54 rue la Boétie, 75008 PARIS (FR).

(72) Inventors: **BOUABOULA, Monsif**; c/o Sanofi 55 Corporate Drive, BRIDGEWATER, NJ 08807 (US). **GUO, Zhuyan**; c/o Sanofi 55 Corporate Drive, BRIDGEWATER, NJ 08807 (US). **POIRIER, Stéphane**; c/o Sanofi 55 Corporate Drive, BRIDGEWATER, NJ 08807 (US). **SHOMALI, Maysoun**; c/o Sanofi 55 Corporate Drive, BRIDGEWATER, NJ 08807 (US). **SUN, Fangxian**; c/o Sanofi 55 Corporate Drive, BRIDGEWATER, NJ 08807 (US).

(74) Agent: **ROMANOWSKI, Caroline**; Sanofi Patent Department, 54 rue la Boétie, 75008 PARIS (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/170793 A1

(54) Title: COMBINATION COMPRISING ALPELISIB AND 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO[7]ANNULENE-2-CARBOXYLIC ACID

(57) Abstract: Herein are provided a combination of alpelisib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)- 1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.